EUVIMEDEUVIMED entdecken
Crossref

Molecular characterization of clear cell adenocarcinoma of the urinary bladder

Shilpy Jha, Anandi Lobo iD, Ankur R Sangoi iD, Shivani R Kandukuri iD, Sourav K Mishra iD, Samriti Arora, Aditi Aggarwal, Shivani Sharma, Ekta Jain iD, Mahmut Akgul iD, Andres M Acosta iD, Niharika Pattnaik und 9 weitere

Histopathology · 2026

DOI: 10.1111/his.70096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2026. Verfasst von Shilpy Jha und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Manipal Hospitals, Bangalore, India. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Adenocarcinoma, Clear Cell. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clear cell adenocarcinoma (CCA) of the urinary tract is a rare genitourinary malignancy that primarily arises in the urethra and bladder. Due to its rarity, the molecular landscape of these tumours remains poorly characterized. In this large series, we aimed to molecularly characterize CCA to gain insights into its pathogenesis and identify potential targets for therapy.

Design

Formalin‐fixed, paraffin‐embedded tumour tissue blocks from 19 cases of CCA were subjected to molecular profiling using a targeted next‐generation sequencing (NGS) panel.

Results

The most common alteration was a gain‐of‐function mutation in PIK3CA (74%), followed by mutations in KRAS (26%), ERBB2 (21%), SMAD4 (21%), RB1 (16%), TP53 (5%), MET (5%) and APC (5%). Thirteen tumours harboured co‐mutations. Five cases showed concurrent PIK3CA and KRAS mutations, while the remaining tumours had either isolated PIK3CA alterations or co‐occurring loss‐of‐function mutations in tumour suppressor genes, including RB1 point mutation, SMAD4 inactivation, APC truncation or TP53 inactivation. Eight patients died of disease, with a mean follow‐up of 14 months (range, 3–31 months). Notably, all eight deceased patients and two of the surviving patients harboured PIK3CA mutations.

Conclusions

In summary, we identified a distinct oncogenic pathway in CCA of the urinary bladder, most commonly involving activation of the PI3K/AKT/mTOR pathway through gain‐of‐function mutations in PIK3CA (74%) and/or KRAS (26%). These tumours frequently harbour loss‐of‐function mutations in tumour suppressor genes ( TP53 , SMAD4 , RB1 and APC ) and point/missense mutations of proto‐oncogenes ( ERBB2 and MET ). Our study also highlights potential therapeutic targets for this aggressive malignancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsAdenocarcinoma, Clear CellHumansMaleAgedFemaleMutationMiddle AgedAged, 80 and overClass I Phosphatidylinositol 3-KinasesAdultSmad4 ProteinHigh-Throughput Nucleotide SequencingProto-Oncogene Proteins p21(ras)Biomarkers, Tumor

Stichwörter der Autor:innen

clear cell adenocarcinomaglandular lesionmolecular profilingtargeted therapyurinary bladder

Substanzen

Class I Phosphatidylinositol 3-KinasesPIK3CA protein, humanSmad4 ProteinProto-Oncogene Proteins p21(ras)Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Manipal Hospitals, Bangalore, India.
  • Department of Pathology, Kapoor Centre of Urology and Pathology, Raipur, India.
  • Department of Pathology, Stanford Medical Center, Stanford, California, USA.
  • Department of Pathology, University of California, Irvine, California, USA.
  • Department of Oncology, All India Institute of Medical Sciences, Bhubaneswar, India.
  • Department of Pathology and Laboratory Medicine, CORE Diagnostics and CORE Group of Reference Laboratories, Gurgaon, India.

ORCID-Profile: Anandi Lobo, Ankur R Sangoi, Shivani R Kandukuri, Sourav K Mishra, Ekta Jain, Mahmut Akgul, Andres M Acosta, Anil V Parwani, Sean R Williamson, Liang Cheng

Zitieren

APA

Jha, S., Lobo, A., Sangoi, A. R., Kandukuri, S. R., Mishra, S. K., Arora, S., Aggarwal, A., Sharma, S., Jain, E., Akgul, M., Acosta, A. M., Pattnaik, N., Kaushal, S., Baisakh, M., Routa, S., Shaker, N., Dhillon, J., Parwani, A. V., Williamson, S. R., …, & Cheng, L. (2026). Molecular characterization of clear cell adenocarcinoma of the urinary bladder. Histopathology. https://doi.org/10.1111/his.70096

Vancouver

Jha S, Lobo A, Sangoi AR, Kandukuri SR, Mishra SK, Arora S, et al. Molecular characterization of clear cell adenocarcinoma of the urinary bladder. Histopathology. 2026. doi:10.1111/his.70096

BibTeX
@article{Jha2026,
  author = {Jha, Shilpy and Lobo, Anandi and Sangoi, Ankur R and Kandukuri, Shivani R and Mishra, Sourav K and Arora, Samriti and Aggarwal, Aditi and Sharma, Shivani and Jain, Ekta and Akgul, Mahmut and Acosta, Andres M and Pattnaik, Niharika and Kaushal, Seema and Baisakh, Manas and Routa, Sudhasmita and Shaker, Nada and Dhillon, Jasreman and Parwani, Anil V and Williamson, Sean R and Mohanty, Sambit K and Cheng, Liang},
  title = {Molecular characterization of clear cell adenocarcinoma of the urinary bladder},
  journal = {Histopathology},
  year = {2026},
  doi = {10.1111/his.70096}
}
Kostenlos starten →